Enliven Therapeutics (NASDAQ:ELVN) CEO Samuel Kintz Sells 3,700 Shares

Key Points

• CEO Samuel Kintz sold 3,700 shares of Enliven Therapeutics at an average price of $20.06, totaling $74,222, reducing his holding by 0.40% to approximately 915,392 shares.
• The stock's 52-week range is between a low of $13.30 and a high of $30.03, with a current trading price of $20.47 and a market capitalization of $1.21 billion.
• Analysts have set a consensus price target of $41.20 for Enliven Therapeutics, with five research firms rating the stock as a "Buy."

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 3,700 shares of the company's stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $20.06, for a total transaction of $74,222.00. Following the transaction, the chief executive officer owned 915,392 shares of the company's stock, valued at approximately $18,362,763.52. This trade represents a 0.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, September 23rd, Samuel Kintz sold 2,800 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.03, for a total transaction of $56,084.00.
• On Friday, September 19th, Samuel Kintz sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.25, for a total transaction of $20,250.00.
• On Wednesday, September 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $19.09, for a total transaction of $95,450.00.
• On Tuesday, August 19th, Samuel Kintz sold 590 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $11,800.00.
• On Monday, August 18th, Samuel Kintz sold 10,393 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.02, for a total transaction of $208,067.86.
• On Thursday, July 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total transaction of $281,500.00.

Enliven Therapeutics Price Performance

NASDAQ ELVN traded up $0.17 during trading hours on Tuesday, hitting $20.47. 402,428 shares of the company's stock traded hands, compared to its average volume of 400,067. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03. The company has a market capitalization of $1.21 billion, a PE ratio of -10.24 and a beta of 0.88. The firm's 50-day moving average is $19.77 and its 200-day moving average is $19.60.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04. Equities research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently made changes to their positions in ELVN. GAMMA Investing LLC lifted its holdings in shares of Enliven Therapeutics by 3,058.1% in the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock worth $53,000 after acquiring an additional 2,630 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Enliven Therapeutics in the 1st quarter worth approximately $60,000. BNP Paribas Financial Markets lifted its holdings in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after acquiring an additional 930 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Enliven Therapeutics by 194.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock worth $106,000 after acquiring an additional 3,490 shares during the last quarter. Finally, KLP Kapitalforvaltning AS lifted its holdings in shares of Enliven Therapeutics by 58.1% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company's stock worth $136,000 after acquiring an additional 2,500 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Robert W. Baird increased their price target on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, June 16th. The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 price target for the company. Finally, HC Wainwright increased their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Enliven Therapeutics currently has an average rating of "Buy" and a consensus price target of $41.20.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.